Assessing the Risk Minimization Activity in Risk Management Plans for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2)-Reference-Cited by-同舟云学术

Assessing the Risk Minimization Activity in Risk Management Plans for Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2)

Published:2021-09-10 Issue:9 Volume:47 Page:464-476
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Jpn. J. Pharm. Health Care Sci.

Author:

Hayashi Tsuyoshi¹,Tachi Tomoya¹,Noguchi Yoshihiro¹,Sugioka Mayuko¹,Aoyama Satoshi²,Tanaka Kazuhide²,Yasuda Masahiro²,Goto Chitoshi²,Yamada Koji³,Mizui Takashi²,Teramachi Hitomi⁴

Affiliation:

1. Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University

2. Department of Pharmacy, Gifu Municipal Hospital

3. Department of Diabetology and Endocrinology, Gifu Municipal Hospital

4. Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://www.jstage.jst.go.jp/article/jjphcs/47/9/47_464/_pdf

Reference15 articles.

1. 1）森　和彦, 医薬品リスク管理計画（RMP）の現状と今後RMPに関する行政の取組み, 薬剤疫学, 2015, 19, 103-108.

2. 2）Mori K, Watanabe M, Horiuchi N, Tamura A, Kutsumi H, The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety, Clin J Gastroenterol, 2014, 7, 103-107.

3. 3）佐村　優, 小川寿子, 仙内光子, 堀慎太郎, 山本彩子, 腰岡　桜, 廣瀬直樹, 関根寿一, SGLT2阻害薬に対する院内採用の評価と使用基準の活用による適正使用支援の有用性に関する検討, 医療薬学, 2017, 43, 80-93.

4. 4）成川　衛, 山田知子, 医薬品リスク管理計画（RMP）における追加のリスク最小化活動の効果の評価 : 患者向け情報資材の効果に関するインターネット調査―ゾフルーザを例として, レギュラトリーサイエンス学会誌, 2020, 10, 87-98.

5. 5）Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, N Engl J Med, 2015, 373, 2117-2128.